First Republic Investment Management Inc. increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 96.3% in the third quarter, HoldingsChannel reports. The firm owned 382,432 shares of the company’s stock after buying an additional 187,563 shares during the period. First Republic Investment Management Inc.’s holdings in AstraZeneca were worth $20,973,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. Fairfield Bush & CO. bought a new position in AstraZeneca during the first quarter worth about $28,000. Panagora Asset Management Inc. boosted its holdings in shares of AstraZeneca by 55.1% during the first quarter. Panagora Asset Management Inc. now owns 11,956 shares of the company’s stock worth $793,000 after acquiring an additional 4,249 shares during the period. BlackRock Inc. boosted its holdings in shares of AstraZeneca by 22.0% during the first quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock worth $495,328,000 after acquiring an additional 1,343,939 shares during the period. Great West Life Assurance Co. Can boosted its holdings in shares of AstraZeneca by 102.7% during the first quarter. Great West Life Assurance Co. Can now owns 525 shares of the company’s stock worth $36,000 after acquiring an additional 266 shares during the period. Finally, Moors & Cabot Inc. boosted its holdings in shares of AstraZeneca by 2.8% during the first quarter. Moors & Cabot Inc. now owns 10,841 shares of the company’s stock worth $719,000 after acquiring an additional 292 shares during the period. Institutional investors own 16.42% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price target on AstraZeneca from £120 ($148.57) to £130 ($160.95) in a research note on Thursday, December 15th. JPMorgan Chase & Co. boosted their price target on AstraZeneca from £125 ($154.76) to £135 ($167.14) in a research note on Tuesday, January 3rd. BMO Capital Markets assumed coverage on AstraZeneca in a research note on Thursday, January 5th. They issued an “outperform” rating for the company. StockNews.com assumed coverage on AstraZeneca in a research note on Wednesday, October 12th. They issued a “buy” rating for the company. Finally, Guggenheim cut their price target on AstraZeneca from £120 ($148.57) to £118 ($146.09) in a research note on Tuesday, October 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, AstraZeneca currently has an average rating of “Hold” and a consensus target price of $9,510.67.
AstraZeneca Stock Performance
AstraZeneca (NASDAQ:AZN – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.07. The company had revenue of $10.98 billion during the quarter, compared to the consensus estimate of $10.98 billion. AstraZeneca had a net margin of 4.52% and a return on equity of 29.40%. On average, equities analysts forecast that AstraZeneca PLC will post 3.33 EPS for the current fiscal year.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.